Gefitinib, bevacizumab and recombinant human endostatin are the first-line treatment drugs for non-small cell lung cancer (NSCLC) with somatic epidermal growth factor receptor (EGFR) mutations in China, and were included in the first and second batches of the price-negotiated anti-cancer drugs (40, 41). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.